Oseltamivir and S-Adenosyl-L-Methionine Combination as Effective Therapeutic Strategy for Suppression of Oxidative Damage in Lung Caused by Influenza Virus Infection in Mice

Drug Res (Stuttg). 2020 Jun;70(6):273-279. doi: 10.1055/a-1147-8824. Epub 2020 Apr 21.

Abstract

Background and objectives: The pathogenesis of influenza infection is associated with two general processes in the body: (a) lung damage based on virus replication; (b) overproduction of free radicals, antioxidant deficiency, and development of oxidative stress. To attack these aspects of flu pathogenesis, we explored the combined effect of the antiviral agent oseltamivir, and s-adenosyl-l-methionine (SAM) as a precursor of the endogenous antioxidant glutathione, in mice infected with influenza virus.

Methods: After inoculation of albino mice with 10 MLD50 of influenza virus A/Aichi/2/68 (H3N2), oseltamivir was applied twice a day, for five days post-infection in doses of 1.25 and 2.5 mg/kg. SAM was administered once a day for 10 days, starting 5 days before infection in doses of 50, 100 and 150 mg/kg.

Results: Monotherapy with SAM did not influence the markers of oxidative stress in the lung. Combination of SAM 50 mg/kg and oseltamivir 2.5 mg/kg affected best the virological parameters - viral titer, protection index, and mean survival time, as well as the biochemical markers of oxidative stress.

Interpretation and conclusions: Combining of SAM and oseltamivir in a dose of 1/4 of optimal therapeutic could be considered as a perspective therapy of influenza viral infection.

MeSH terms

  • Animals
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Synergism
  • Drug Therapy, Combination / methods
  • Humans
  • Influenza A Virus, H3N2 Subtype / drug effects*
  • Influenza A Virus, H3N2 Subtype / isolation & purification
  • Influenza, Human / drug therapy*
  • Influenza, Human / pathology
  • Influenza, Human / virology
  • Lung / drug effects*
  • Lung / pathology
  • Lung / virology
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Oseltamivir / pharmacology*
  • Oseltamivir / therapeutic use
  • Oxidative Stress / drug effects
  • S-Adenosylmethionine / pharmacology*
  • S-Adenosylmethionine / therapeutic use
  • Virus Replication / drug effects

Substances

  • Antioxidants
  • Antiviral Agents
  • Oseltamivir
  • S-Adenosylmethionine